Correction to: The influence of treatment on hormone receptor subgroups and breast cancer-specific mortality within US integrated healthcare systems

Correction to: Cancer Causes & Control (2022) 33:1019–1023 https://doi.org/10.1007/s10552-022-01589-4

Following publication of the original article [1] the authors identified that the name of Erin J Aiello Bowles was incorrectly spelled. The correct spelling is shown above. In addition, the legend of Fig. 1 and Table 1 were incorrectly printed and digits in the revised values were mixed with digits in the original values. The corrected versions of Fig. 1 and Table 1 are included.

Fig. 1

Cumulative incidence of breast cancer-specific mortality accounted for competing risks (non-breast cancer mortality) among 11,737 women who survived ≥ 1 years after being diagnosed with a first primary breast cancer with known ER/PR status at Kaiser Permanente Colorado  (n  = 5068 between 1994 and 2014) or Kaiser Permanente Washington (n = 6669 between 1990 and 2016). P value was based on the Gray’s test. One patient diagnosed with ER+/PR+ had a breast cancer-related death 25 years after her initial diagnosis and this event does not appear in the table above

Table 1 Risk of breast cancer cancer-specific mortality for hormone receptor subgroups in Kaiser Permanente Colorado and Kaiser Permanente Washington (N = 11,737)